Carabrone covalently binds to Trx1at cysteine 73 and then inhibits enzymatic activity, which inhibits differentiation and induces apoptosis in osteoclasts. Carabrone prevents bone resorption in vivo and in vitro. Targeting Trx1 represents a promising target for the treatment of bone-resorptive diseases.